What is Regenxbio's D&A?

Regenxbio (RGNX) reported D&A of $3.86M in Q1 2026.

How has Regenxbio's D&A changed year-over-year?

Regenxbio's D&A decreased by 2.5% year-over-year, from $3.96M to $3.86M.

What is the long-term trend for Regenxbio's D&A?

Over 4 years (2021 to 2025), Regenxbio's D&A has grown at a 13.0% compound annual growth rate (CAGR), from $9.56M to $15.62M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Regenxbio RGNX D&A

D&A at other companies

Regeneron PharmaceuticalsREGN

$123.2M-2.9%

Sarepta Therapeutics, Inc.SRPT

$10.59M+6.2%

BiogenBIIB

$204.4M+11.6%

BioMarin PharmaceuticalsBMRN

$16.41M-25.6%

EyePoint, Inc. EYPT

$636K+28.0%

Ultragenyx PharmaceuticalRARE

$8M-11.1%

Other financials

Income statement

See full

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

See full

Cash & equivalents$15.2M-88.3%

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

See full

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

See full

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

See full

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

See full

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regenxbio's D&A?: Regenxbio (RGNX) reported D&A of $3.86M in Q1 2026.
How has Regenxbio's D&A changed year-over-year?: Regenxbio's D&A decreased by 2.5% year-over-year, from $3.96M to $3.86M.
What is the long-term trend for Regenxbio's D&A?: Over 4 years (2021 to 2025), Regenxbio's D&A has grown at a 13.0% compound annual growth rate (CAGR), from $9.56M to $15.62M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.